Xenon Pharmaceuticals Inc. (XENE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
Is Xenon Pharmaceuticals Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Xenon Pharmaceuticals Inc. (XENE) trades at $37.41 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Xenon Pharmaceuticals Inc.
Market cap $4B · 52 weeks $33 – $71 (47 % below the high) · P/E no earnings · Dividend none · Next earnings November 2, 2026 · expected EPS $-1.13 · Closing price, Oct 30 · accounts published Aug 6.
- Valuation: P/Sales 176× (no earnings).
- Balance sheet: Grey zone (watch).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- Market cap / Cash 5.4×, fails.
- Cash Runway 24 months, borderline.
- Total Debt 0.0×, passes.
- R&D / Market cap 10.2 %, passes, near the threshold.
- Annual cash burn $3.52, info.
Against its peers (reference peers) — Xenon Pharmaceuticals Inc.: P/E —; EV/EBITDA —; ROIC -35.1 %; $3.6B. Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B), Jazz Pharmaceuticals plc (P/E 14.8×; EV/EBITDA 10.2×; ROIC 14.5 %; $14.0B), Neurocrine Biosciences, Inc. (P/E 21.4×; EV/EBITDA 16.2×; ROIC 13.2 %; $14.9B).
Profitability
| Return on Equity | -43.98% |
| Return on Invested Capital | -35.10% |
| Return on Assets | -31.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 21.02 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.94 |
Price Performance
| 1 month | -1.60% |
| 3 months | -39.91% |
| Year-to-date | -16.53% |
| 1 year | -10.76% |
| 3 years | +13.12% |
| 5 years | +9.77% |
| 10 years | +385.84% |
Related companies: NBIX · JAZZ · AXSM · PRAX · ACAD · DNLI · SUPN
Explore sector: Healthcare · Biotechnology
More sections of XENE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks